NCT01841021 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)

Study Title
Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30 (NCT01841021)

Trial Description
The main purpose of this study is to test if brentuximab vedotin (also known as SGN-35) has an effect on cancer in patients with a certain type of large B-cell lymphoma. The side effects (unwanted effects) of brentuximab vedotin in patients with this certain type of large B-cell lymphoma will also be studied. It is not known if brentuximab vedotin is better or worse than other treatment patients might be given.

This trial is sponsored by Moffitt Cancer Center & Research Institute/Seattle Genetics. [1]

Study Data

  • Condition: Peripheral T-Cell Lymphoma
  • Interventions:
  • Phase: 0
  • Estimated Enrollment: 1
  • Start: April 2014
  • Estimated Completion: June 2017
  • Last verified: June 2016

Study Schematic

Screen Shot 2016-07-18 at 3.15.36 PM

Click here to Return to Drug map


Last Editorial review: July 15, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.